By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) announced a study that demonstrated that its oral treatment devices are an effective and safe alternative to CPAP for moderate and severe obstructive sleep apnea. The company presented its research findings at the...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) said it named Megan Yung as Chief Strategy Officer and General Counsel. Ms. Yung brings expertise from her previous roles at SQZ Biotechnologies and her background in intellectual property law, Eterna said...

By Exec Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), said revenue surged 55 percent in the first quarter from a year earlier. Revenue totaled $5.8 million, up from $3.7 million in the first quarter of 2022, it said in a...

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license...

  By Healthcare Edge Editorial Staff Biopharma company Ocean Biomedical (NASDAQ: OCEA) reported positive findings published in peer-reviewed journal Cancer Research, bolstering evidence of the potential impact of its anti-Chi3L1 antibody in suppressing severe glioblastoma tumor growth. “This is a...

IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with senior management from Thirty Madison . The in-person interview featured President Michelle Carnahan and CFO Quan Zhang joined by IPO Edge Editor-in-Chief John Jannarone...

Healthcare Edge sister platform IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Catherine Roggero-Lovisi, CEO of Modern Meadow. Ms. Roggero-Lovisi spoke with IPO Edge Editor-in-Chief John Jannarone about her prior role at L’Oréal S.A., the advantages of a...

By Exec Edge Editorial Staff SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes. SAB-185 demonstrated benefit in...

Healthcare Edge sister platform IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with the Juliette Han, CFO and COO of Cambrian Bio. Ms. Han spoke to Editor-at-Large Jarrett Banks about her background as a neuroscientist,...

By Daniella Parra Lunaphore said it completed CHF40 million in Series D1 funding led by Ernst-Göhner Stiftung Beteiligungen (EGSB). The Swiss life sciences company said it plans to use the funding to strengthen its portfolio offering in spatial biology and support...